RxDoctor Payments Data

Jennifer Merritt, MD

Ophthalmology · Little River, SCNPI 1710050471

Payments from drug & device makers

$2,548in general payments, 2019–2025

Across 120 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$504
  • Kala Pharmaceuticals, Inc.$455
  • AbbVie$422
  • Alcon$371
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$169
  • Bausch & Lomb Americas Inc.$158
  • plus $468 from 10 others

What the payments were for

  • Food & beverage$2,548100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,548 in reported general payments places this provider in the 55th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$559,649
Medicare patients
1,288
Services billed
5,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost227$113,629
VyzultaLatanoprostene Bunod144$66,863
IlevroNepafenac158$57,903
RestasisCyclosporine38$54,121
BesivanceBesifloxacin Hcl233$51,446
ProlensaBromfenac Sodium99$34,252
XdemvyLotilaner14$26,563
Cyclosporine34$22,953
XiidraLifitegrast14$22,221
Prednisolone Acetate647$19,625
CombiganBrimonidine Tartrate/Timolol51$15,653
Alphagan PBrimonidine Tartrate34$12,346
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol73$11,711
Brimonidine Tartrate160$11,522
Difluprednate112$10,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$422$195,748350 claims
Bausch & Lomb Americas Inc.Vyzulta, Xiidra$158$89,084158 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa, Loteprednol Etabonate$169$88,527352 claims
NovartisIlevro$119$57,903158 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$31$26,56314 claims
Sun Pharmaceutical Industries Inc.Cequa$504$8,74112 claims
AlconSimbrinza$371$5,21314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Little River

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →